Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00738530 · BASELINE

Baseline characteristics

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy · Source last updated 2016-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      327
    2. group Id
      BG001
      value
      322
    3. group Id
      BG002
      value
      649
    units
    Participants
groups
  1. description
    Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    BG000
    title
    Bevacizumab + IFN-Alfa-2A
  2. description
    Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    BG001
    title
    Placebo + IFN-Alfa-2A
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.12
          value
          60.1
        2. group Id
          BG001
          spread
          10.89
          value
          59.4
        3. group Id
          BG002
          spread
          10.51
          value
          59.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          105
        2. group Id
          BG001
          value
          87
        3. group Id
          BG002
          value
          192
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          222
        2. group Id
          BG001
          value
          235
        3. group Id
          BG002
          value
          457
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent-to-treat population (ITT) included all participants randomized into the study.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      327
    2. group Id
      BG001
      value
      322
    3. group Id
      BG002
      value
      649
    units
    Participants
groups
  1. description
    Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    BG000
    title
    Bevacizumab + IFN-Alfa-2A
  2. description
    Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
    id
    BG001
    title
    Placebo + IFN-Alfa-2A
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          10.12
          value
          60.1
        2. group Id
          BG001
          spread
          10.89
          value
          59.4
        3. group Id
          BG002
          spread
          10.51
          value
          59.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          105
        2. group Id
          BG001
          value
          87
        3. group Id
          BG002
          value
          192
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          222
        2. group Id
          BG001
          value
          235
        3. group Id
          BG002
          value
          457
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent-to-treat population (ITT) included all participants randomized into the study.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice